A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...
Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...
12d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
According to the Centers for Disease Control and Prevention (CDC), losing about one to two pounds per week will lead to long-term weight loss ... under the brand names Zepbound and Monjouro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback